News · 18 November 2026

FDA rejects lung cancer drug ivonescimab

18 November 2026 · Washington · Health · US · Business

FDA rejects lung cancer drug ivonescimab
Picture: STATNEWS · STATNEWS syndication feed

The FDA has rejected ivonescimab, a lung cancer drug from Summit Therapeutics and Chinese drugmaker Akeso. It slowed the cancer in a global trial. But regulators said it did not show that patients lived longer. Some had hoped it could rival Keytruda.

Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.

Also on 18 November 2026